 |
BioWorld-Insight-2010-01-25
Ironwood Boosts IPO Terms and Industry's Fresh Hope
Tarceva Reprieve? FDA Delay Could Mean Little Either Way
Last week's Tarceva news - unlike the thumbs-down vote by an FDA advisory panel in December - came as little surprise: The action date for a decision on the already-marketed EGFR drug in a new indication, first-line maintenance therapy for non-small-cell lung cancer, has been set back 90 days to April 18.